RCT | Dual endothelin antagonist Aprocitentan is effective for resistant hypertension.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentaries:

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION – TCTMD

Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension – PRECISION – American College of Cardiology